Management of COVID-19 in patients with pulmonary arterial hypertension

In this review, we discuss the evidence regarding the course and management of COVID-19 in patients with pulmonary arterial hypertension (PAH), the challenges in PAH management during the pandemic and, lastly, the long-term complications of COVID-19 in relation to pulmonary vascular disease. The inherent PAH disease characteristics, as well as age, comorbidities and the patient ’s functional status act synergistically to define prognosis of COVID-19 in patients with PAH. Management of COVID-19 should follow the general guidelines, while PAH-targeted therapies should be continued. The pandemic has caused a shift towards telemedicine in the chronic care of PAH patients. Wh ether COVID-19 could predispose to the development of chronic pulmonary hypertension is a subject of future investigation.
Source: Heart Failure Clinics - Category: Cardiology Authors: Source Type: research